|
Gene: FA2H |
Gene summary for FA2H |
Gene summary. |
Gene information | Species | Human | Gene symbol | FA2H | Gene ID | 79152 |
Gene name | fatty acid 2-hydroxylase | |
Gene Alias | FAAH | |
Cytomap | 16q23.1 | |
Gene Type | protein-coding | GO ID | GO:0001949 | UniProtAcc | Q7L5A8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79152 | FA2H | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.09e-10 | 7.31e-01 | -0.1808 |
79152 | FA2H | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.86e-04 | 6.24e-01 | -0.0811 |
79152 | FA2H | HTA11_78_2000001011 | Human | Colorectum | AD | 1.29e-03 | 4.48e-01 | -0.1088 |
79152 | FA2H | HTA11_347_2000001011 | Human | Colorectum | AD | 3.29e-15 | 7.00e-01 | -0.1954 |
79152 | FA2H | HTA11_411_2000001011 | Human | Colorectum | SER | 3.76e-05 | 1.29e+00 | -0.2602 |
79152 | FA2H | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.90e-02 | 4.52e-01 | -0.1207 |
79152 | FA2H | HTA11_83_2000001011 | Human | Colorectum | SER | 6.16e-06 | 6.88e-01 | -0.1526 |
79152 | FA2H | HTA11_696_2000001011 | Human | Colorectum | AD | 5.37e-13 | 7.16e-01 | -0.1464 |
79152 | FA2H | HTA11_866_2000001011 | Human | Colorectum | AD | 5.51e-07 | 4.51e-01 | -0.1001 |
79152 | FA2H | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.71e-03 | 4.66e-01 | -0.059 |
79152 | FA2H | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.23e-03 | -2.59e-01 | 0.3005 |
79152 | FA2H | A015-C-203 | Human | Colorectum | FAP | 3.36e-08 | -1.80e-01 | -0.1294 |
79152 | FA2H | A002-C-201 | Human | Colorectum | FAP | 1.32e-04 | -1.94e-01 | 0.0324 |
79152 | FA2H | A001-C-108 | Human | Colorectum | FAP | 1.87e-04 | -1.66e-01 | -0.0272 |
79152 | FA2H | A002-C-205 | Human | Colorectum | FAP | 1.19e-06 | -1.84e-01 | -0.1236 |
79152 | FA2H | A015-C-006 | Human | Colorectum | FAP | 2.07e-03 | -1.42e-01 | -0.0994 |
79152 | FA2H | A015-C-106 | Human | Colorectum | FAP | 2.17e-03 | -1.04e-01 | -0.0511 |
79152 | FA2H | A002-C-114 | Human | Colorectum | FAP | 1.04e-05 | -1.89e-01 | -0.1561 |
79152 | FA2H | A015-C-104 | Human | Colorectum | FAP | 1.03e-10 | -2.13e-01 | -0.1899 |
79152 | FA2H | A001-C-014 | Human | Colorectum | FAP | 9.11e-06 | -2.13e-01 | 0.0135 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0042633 | Colorectum | CRC | hair cycle | 21/2078 | 107/18723 | 6.56e-03 | 4.70e-02 | 21 |
GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
GO:00435888 | Esophagus | ESCC | skin development | 163/8552 | 263/18723 | 6.48e-08 | 1.14e-06 | 163 |
GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
GO:00464673 | Esophagus | ESCC | membrane lipid biosynthetic process | 91/8552 | 142/18723 | 7.19e-06 | 7.19e-05 | 91 |
GO:000991310 | Esophagus | ESCC | epidermal cell differentiation | 122/8552 | 202/18723 | 1.69e-05 | 1.51e-04 | 122 |
GO:00425524 | Esophagus | ESCC | myelination | 85/8552 | 134/18723 | 2.51e-05 | 2.13e-04 | 85 |
GO:00072724 | Esophagus | ESCC | ensheathment of neurons | 86/8552 | 136/18723 | 2.68e-05 | 2.24e-04 | 86 |
GO:00083664 | Esophagus | ESCC | axon ensheathment | 86/8552 | 136/18723 | 2.68e-05 | 2.24e-04 | 86 |
GO:00066652 | Esophagus | ESCC | sphingolipid metabolic process | 96/8552 | 155/18723 | 3.21e-05 | 2.66e-04 | 96 |
GO:00420636 | Esophagus | ESCC | gliogenesis | 172/8552 | 301/18723 | 3.75e-05 | 3.04e-04 | 172 |
GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
GO:00100016 | Esophagus | ESCC | glial cell differentiation | 129/8552 | 225/18723 | 2.73e-04 | 1.65e-03 | 129 |
GO:00160538 | Esophagus | ESCC | organic acid biosynthetic process | 175/8552 | 316/18723 | 3.04e-04 | 1.82e-03 | 175 |
GO:00066642 | Esophagus | ESCC | glycolipid metabolic process | 63/8552 | 100/18723 | 3.55e-04 | 2.06e-03 | 63 |
GO:19035092 | Esophagus | ESCC | liposaccharide metabolic process | 63/8552 | 101/18723 | 5.25e-04 | 2.90e-03 | 63 |
GO:00140373 | Esophagus | ESCC | Schwann cell differentiation | 28/8552 | 40/18723 | 1.61e-03 | 7.50e-03 | 28 |
GO:00315798 | Esophagus | ESCC | membrane raft organization | 19/8552 | 25/18723 | 2.03e-03 | 9.08e-03 | 19 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FA2H | SNV | Missense_Mutation | novel | c.709N>A | p.Leu237Met | p.L237M | Q7L5A8 | protein_coding | deleterious(0.01) | possibly_damaging(0.776) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
FA2H | SNV | Missense_Mutation | rs387907039 | c.703N>T | p.Arg235Cys | p.R235C | Q7L5A8 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-C5-A1ME-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FA2H | SNV | Missense_Mutation | c.950A>G | p.Tyr317Cys | p.Y317C | Q7L5A8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3506-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FA2H | SNV | Missense_Mutation | c.581N>A | p.Gly194Asp | p.G194D | Q7L5A8 | protein_coding | tolerated(0.12) | benign(0.029) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
FA2H | SNV | Missense_Mutation | novel | c.938N>C | p.Met313Thr | p.M313T | Q7L5A8 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FA2H | SNV | Missense_Mutation | novel | c.538N>A | p.Val180Met | p.V180M | Q7L5A8 | protein_coding | tolerated(0.22) | benign(0.189) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FA2H | SNV | Missense_Mutation | c.1016N>G | p.His339Arg | p.H339R | Q7L5A8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0GH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FA2H | SNV | Missense_Mutation | c.919N>T | p.Gly307Cys | p.G307C | Q7L5A8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
FA2H | SNV | Missense_Mutation | novel | c.282G>T | p.Glu94Asp | p.E94D | Q7L5A8 | protein_coding | tolerated(0.14) | benign(0.236) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FA2H | SNV | Missense_Mutation | novel | c.913N>A | p.Leu305Ile | p.L305I | Q7L5A8 | protein_coding | tolerated(0.07) | probably_damaging(0.999) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |